Patel Sanjiv 4

4 · Relay Therapeutics, Inc. · Filed Jul 8, 2026

AI-generated summary of this filing

Updated Jul 8, 2026

Relay Therapeutics (RLAY) CEO Sanjiv Patel Sells 48,199 Shares

What Happened

Sanjiv Patel, President, CEO and Director of Relay Therapeutics, reported two transactions: he sold 48,199 shares in an open-market sale on 2026-07-07 for weighted average proceeds of $943,736 (weighted avg price $19.58), and he acquired 3,056 shares under the company’s 2020 Employee Stock Purchase Plan (ESPP) on 2026-06-30 for $6.95 per share, totaling $21,239. The sale was effected under a pre-established Rule 10b5-1 trading plan.

Key Details

Sale date and price: 2026-07-07 — 48,199 shares sold; weighted average price $19.58; price range across trades $18.52–$20.20. (Reporting person can provide breakdown on request.)
Purchase date and price: 2026-06-30 — 3,056 ESPP shares acquired at $6.95 each (85% of the issuer’s closing price on Jan 2, 2026).
Plan/authorization: Sale effected pursuant to a Rule 10b5-1 plan adopted Oct 30, 2025; ESPP purchase exempt under Rule 16b-3 and voluntarily reported.
Trust holdings: Filing notes certain shares are held in irrevocable trusts for family members and the reporting person disclaims beneficial ownership of those shares.
Shares owned after transaction: Not specified in this Form 4.
Filing timeliness: Form 4 filed 2026-07-08 for transactions reported through 2026-07-07 (filed the next day).

Context

The ESPP purchase is a routine employee benefit (discounted purchase) and the purchase price reflects the plan’s 85% pricing. The sale was made under a 10b5-1 plan, indicating it was pre-arranged rather than an ad hoc trade. As always, these disclosures are factual records of insider activity and do not, by themselves, indicate company performance or the insider’s private views.

Form 4

Period: 2026-07-07

DirectorPresident and CEO

Transactions

Holdings

Footnotes (5)

[F1]The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
[F2]In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026.
[F3]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
[F4]This transaction was executed in multiple trades at prices ranging from $18.52 to $20.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F5]These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Signature

/s/ Soo-Yeun Lim, as attorney-in-fact|2026-07-08

1 file